CGT-1881

**CGT-1881** is an investigational **oral small-molecule CXCR4 antagonist** developed by **CGeneTech** for **blood cancers**, particularly hematologic malignancies. Available context indicates that it is positioned as an original oral CXCR4-targeted program in China, with development spanning **hematopoietic stem cell mobilization** and oncology applications. Clinical development described in the provided materials includes **Phase 1** evaluation in healthy volunteers for safety and tolerability after single oral doses, and **Phase 2a** study activity in patients with **non-Hodgkin lymphoma** or **multiple myeloma** assessing safety, tolerability, and preliminary efficacy.